Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Ever Valinject GmbH currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner and is situated within 1 distinct art unit. This concentration indicates that the company's current active prosecution is focused on a specific matter, requiring a targeted strategy to address the requirements of the assigned examiner and art unit.
The busiest examiner for this portfolio is BEANE, RANDALL L, who is responsible for 1 pending office action. Because this individual is the only examiner currently handling an active case for the company, their perspective and examination style will be the primary factor in the immediate progress of the portfolio. Practitioners should review the past decisions of the named examiner to prepare a response to the outstanding matter.
The presence of 1 pending office action and 1 distinct art unit means that the administrative requirements for this portfolio relate to these specific points of contact. The absence of other pending matters means that the company's current advancement in its technology field depends on the outcome of this prosecution. Practitioners should focus on building an argument to navigate the case under the assigned official.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BEANE, RANDALL L | 1 | 32.9% | +36.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18037944 | AQUEOUS SOLUTION | BEANE, RANDALL L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18037944 | AQUEOUS SOLUTION | BEANE, RANDALL L | — |
| Art Unit | Apps |
|---|---|
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18037944 | AQUEOUS SOLUTION | BEANE, RANDALL L | 1654 | §103§112 | Final Rejection | — | Pending | May 19, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEver Valinject GmbH has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Randall L Beane has the most, with 1 of Ever Valinject GmbH's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
